|
Glioma
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Our findings demonstrate that FUBP1 expression levels are increased in all glioma subtypes as compared with normal central nervous system (CNS) control tissue and are associated with increased proliferation.
|
24117486 |
2014 |
|
Glioma
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the critical chromatin modifier ATRX and mutations in CIC and FUBP1, which are potent regulators of cell growth, have been discovered in specific subtypes of gliomas, the most common type of primary malignant brain tumors.
|
22869205 |
2012 |
|
Glioma
|
0.320 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Sciatic Neuropathy
|
0.200 |
Biomarker
|
disease |
RGD |
FBP1 and p27kip1 expression after sciatic nerve injury: implications for Schwann cells proliferation and differentiation.
|
23939805 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
FUBP1 is also described either as an oncoprotein or a tumor suppressor.
|
30343319 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PUF60 is a splicing variant of far upstream element binding protein 1-interacting repressor, which is abnormally expressed in a variety of tumors and is closely involved in their progression.
|
30697074 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, we show that FUBP1 promotes tumor cell proliferation and migration and regulates the cancer cell immunity by increasing the PD-L1 expression mediated by Myc in pancreatic cancer cells.
|
30301530 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results showed that the PVT1 expression in tumor tissues was higher than that in normal tissues, which was significantly correlated with the expression of c-Myc and three c-Myc regulating genes FUBP1, EZH2, and NPM1 and also correlated with the expression of two other PVT1-associated transcript factors nuclear factor-κB and myocyte-specific enhancer factor 2A.
|
28381186 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The trunk alterations that existed throughout the course were restricted to IDH1 mutation, 1p/19q-codeletion, and TERT promoter mutation, and mutation of the known candidate tumor suppressor genes CIC and FUBP1 were not consistently observed between primary and recurrent tumors.
|
28270234 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High levels of FUBP1 mRNA expression were associated with higher tumor stage and tumor size.
|
28076379 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition to correlation between expression of FUBP1 and tumor grade, we also confirmed the correlation of FUBP1, c-Myc, and Ki-67 expression by twos.
|
26490982 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical analysis revealed loss of CIC or FUBP1 protein expression in 36% (20/55) and 16% (9/55) of oligodendroglial tumors examined.
|
24030748 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To date, all reported FUBP1 mutations have been predicted to inactivate FUBP1, which suggests that in contrast to most other tumours FUBP1 may act as a tumour suppressor in oligodendrogliomas.
|
24117486 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
One of these tumors also had a deleterious mutation in FUBP1.
|
24086756 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, FUBP1 homozygous deletion was detected in one case suggesting a putative tumor suppressor role of FUBP1 in AOD.Our study showed that the genomic and pathological analyses of AOD are synergistic in detecting relevant clinical and biological subgroups of AOD.
|
23071531 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Among other changes, we found that the CIC gene (homolog of the Drosophila gene capicua) on chromosome 19q was somatically mutated in six cases and that the FUBP1 gene [encoding far-upstream element (FUSE) binding protein] on chromosome 1p was somatically mutated in two tumors.
|
21817013 |
2011 |
|
oligodendroglioma
|
0.080 |
Biomarker
|
disease |
BEFREE |
More recently described biomarkers, including the non-balanced translocation leading to 1p/19q codeletion, promoter hypermethylation of the MGMT gene, mutations of the IDH1 or IDH2 gene, and mutations of FUBP1 (on 1p) or CIC (on 19q), have greatly enhanced our understanding of oligodendroglioma biology, although their diagnostic, prognostic, and predictive roles are less clear.
|
25943885 |
2015 |
|
oligodendroglioma
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Causal genetic changes in oligodendrogliomas (OD) with 1p/19q co-deletion include mutations in IDH1, IDH2, CIC, FUBP1, TERT promoter and NOTCH1.
|
25694352 |
2015 |
|
Well Differentiated Oligodendroglioma
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Causal genetic changes in oligodendrogliomas (OD) with 1p/19q co-deletion include mutations in IDH1, IDH2, CIC, FUBP1, TERT promoter and NOTCH1.
|
25694352 |
2015 |
|
Well Differentiated Oligodendroglioma
|
0.080 |
Biomarker
|
disease |
BEFREE |
More recently described biomarkers, including the non-balanced translocation leading to 1p/19q codeletion, promoter hypermethylation of the MGMT gene, mutations of the IDH1 or IDH2 gene, and mutations of FUBP1 (on 1p) or CIC (on 19q), have greatly enhanced our understanding of oligodendroglioma biology, although their diagnostic, prognostic, and predictive roles are less clear.
|
25943885 |
2015 |
|
oligodendroglioma
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Using this approach, we detected a to-date undescribed FUBP1 mutation in an oligodendroglioma.
|
24117486 |
2014 |
|
Well Differentiated Oligodendroglioma
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Using this approach, we detected a to-date undescribed FUBP1 mutation in an oligodendroglioma.
|
24117486 |
2014 |
|
oligodendroglioma
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
The meeting consisted of 3 scientific sessions ranging from neuropathology of IDH1 mutations; CIC, ATRX, and FUBP1 mutations in oligodendrogliomas and astrocytomas; and IDH1 mutations as therapeutic targets.
|
23373454 |
2013 |
|
Well Differentiated Oligodendroglioma
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
The meeting consisted of 3 scientific sessions ranging from neuropathology of IDH1 mutations; CIC, ATRX, and FUBP1 mutations in oligodendrogliomas and astrocytomas; and IDH1 mutations as therapeutic targets.
|
23373454 |
2013 |
|
oligodendroglioma
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
CIC and FUBP1 mutations occurred frequently in oligodendrogliomas (46% and 24%, respectively) but rarely in astrocytomas or oligoastrocytomas ( more than 10%).
|
22869205 |
2012 |